A judge in South Carolina has ruled that Janssen Pharmaceutica — a subsidiary of Johnson & Johnson — must pay the state $327 million for deceptive drug marketing, according to a Wall Street Journal report.
A jury concluded earlier this year that the company misled physicians about the safety and effectiveness of its antipsychotic drug, Risperdal, by downplaying the drug's association with diabetes. The jury ruled in March that this was a violation of the state's unfair trade practices act.
New Brunswick, N.J-based Johnson & Johnson has said it will appeal the court's order. Risperdal has been subject to litigation recently, and Johnson & Johnson recently set aside a reserve related to the federal investigations over Risperdal sales and marketing practices. https://www.beckersasc.com/stark-act-and-fraud-abuse-issues/johnson-a-johnson-reserves-money-in-federal-probe-over-risperdal.html
Read the Wall Street Journal report on Johnson& Johnson and Risperdal.
Related Articles on Pharmaceutical Fraud:
Drugmaker Serono Pays $44M to Settle False Claims Allegations
Forest Laboratories CEO Howard Solomon May Face Ban From Federal Health Programs
Drugmaker Cardinal Health Pays $8M to Settle Kickback Allegations
A jury concluded earlier this year that the company misled physicians about the safety and effectiveness of its antipsychotic drug, Risperdal, by downplaying the drug's association with diabetes. The jury ruled in March that this was a violation of the state's unfair trade practices act.
New Brunswick, N.J-based Johnson & Johnson has said it will appeal the court's order. Risperdal has been subject to litigation recently, and Johnson & Johnson recently set aside a reserve related to the federal investigations over Risperdal sales and marketing practices. https://www.beckersasc.com/stark-act-and-fraud-abuse-issues/johnson-a-johnson-reserves-money-in-federal-probe-over-risperdal.html
Read the Wall Street Journal report on Johnson& Johnson and Risperdal.
Related Articles on Pharmaceutical Fraud:
Drugmaker Serono Pays $44M to Settle False Claims Allegations
Forest Laboratories CEO Howard Solomon May Face Ban From Federal Health Programs
Drugmaker Cardinal Health Pays $8M to Settle Kickback Allegations